Pfizer Inc. (PFE)
| Market Cap | 157.70B |
| Revenue (ttm) | 55.09B |
| Net Income (ttm) | -309.00M |
| Shares Out | 5.67B |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | 11.05 |
| Dividend | $1.68 (6.04%) |
| Ex-Dividend Date | Jul 26, 2024 |
| Volume | 16,889,775 |
| Open | 28.22 |
| Previous Close | 28.22 |
| Day's Range | 27.69 - 28.28 |
| 52-Week Range | 25.20 - 37.80 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 35.86 (+28.85%) |
| Earnings Date | Jul 30, 2024 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]
Financial Performance
In 2023, Pfizer's revenue was $58.50 billion, a decrease of -41.70% compared to the previous year's $100.33 billion. Earnings were $2.12 billion, a decrease of -93.25%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $35.86, which is an increase of 28.85% from the latest price.
News
Weighing the Future of Weight Loss Drugs
How are obesity drugs impacting other industries? Julia Angeles discusses the future of weight loss drugs.
UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case
London's High Court on Tuesday ruled that one of Moderna's patents relating to technology key to the development of vaccines for COVID-19 was invalid, but that another was valid and had been infringed...
Pfizer And Moderna Vaccines Not Linked To Birth Defects, Study Finds
There is no evidence of major birth defects in babies born to mothers vaccinated against COVID-19 during the first trimester of pregnancy, according to new research published in JAMA Pediatrics on Mon...
Cyrus Taraporevala Elected to Pfizer's Board of Directors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. Mr. Taraporevala, age 57, was also appointed to ...
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
Pfizer appears to be on its way toward stabilizing its business and winning back Wall Street's favor after the sudden decline of its Covid business. But the company is struggling to balance that with ...
Daily Dividend Report: AT&T, Kroger, Matson, Pfizer, Edison
The board of directors of AT&T today declared a quarterly dividend of $0.2775 per share on the company's common shares. Dividends on the common stock are payable on August 1, 2024, to stockholders of ...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) ...
Pfizer Declares Third-Quarter 2024 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 third-quarter 2024 dividend on the company's common stock, payable September 3, 2024, to...
Vaccine makers' stocks fall as CDC advisers shift RSV-shot recommendations
Shares of vaccine makers Pfizer Inc., GSK PLC and Moderna Inc. dropped Wednesday as advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinate...
Alnylam's stock surges as heart drug vies with a Pfizer blockbuster
Alnylam Pharmaceuticals Inc.'s stock ALNY, +5.27% jumped nearly 40% premarket on Monday after the company released results of a late-stage trial for a heart drug that analysts see competing with a key...
Palantir and Pfizer CEOs meet U.S. Senators to press for Israel support and hostage release
Alex Karp, Palantir CEO and Albert Bourla, Pfizer CEO, sit down with CNBC's Sara Eisen to discuss the Israel-Hamas War and antisemitism.
Pfizer & Palantir CEOs speak out on Israel-Hamas war and antisemitism
Alex Karp, Palantir CEO and Albert Bourla, Pfizer CEO, sit down with CNBC's Sara Eisen to discuss the Israel-Hamas War and antisemitism.
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, ...
Pfizer stock price analysis: how PFE became a fallen angel
Pfizer (NYSE: PFE) stock price has crashed hard in the past few years as demand for Covid-19 vaccines faded globally. It was trading at $28 on Monday, down from the pandemic high of $55.56.
Kansas sues Pfizer, saying it misled the public over COVID-19 vaccine
The state of Kansas has filed a lawsuit against Pfizer alleging the company misled the public about the safety and effectiveness of its COVID-19 vaccine including by working to censor critical informa...
Kansas sues Pfizer alleging it ‘misled' the public about safety of COVID vaccine
Kansas Attorney General Kris Kobach says Pfizer ‘violated' the Consumer Protection Act on ‘The Bottom Line.' #foxbusiness #thebottomline
Pfizer sued by Kansas for allegedly hiding COVID vaccine risks, making false claims
The lawsuit claims that, beginning shortly after the vaccine's rollout in early 2021, Pfizer concealed evidence that the shot was linked to pregnancy complications, including miscarriage, as well as i...
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit
The U.S. state of Kansas on Monday sued Pfizer , accusing the company of misleading the public about its COVID-19 vaccine by hiding risks while making false claims about its effectiveness.
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech SE's BNTX partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.
Pfizer's COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading Claims
The state of Kansas has reportedly filed a lawsuit against pharmaceutical giant Pfizer, Inc. PFE, accusing the company of violating consumer protection laws related to its COVID-19 vaccine.
Will Pfizer Stock Rebound To Its 2021 Highs Of $60?
Pfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. In contrast, Merck stock is up 36% over this period.
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily p...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Shares of Sarepta Therapeutics Inc. SRPT, -1.15% gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial.
Pfizer's gene therapy for a muscle-wasting disorder misses main goal of late-stage study
Pfizer said on Wednesday its experimental gene therapy for a type of muscle-wasting disorder did not meet the main goal of a late-stage trial.
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-d...